Abstract
Adeno-associated virus (AAV) is a small, non-enveloped virus used as vector in gene therapy, mainly produced in human cells and in baculovirus systems. Intense studies on these platforms led to the production of vectors with titers between 103 and 105 viral genomes (vg) per cells. In spite of this, vector yields need to be improved to satisfy the high product demands of clinical trials and future commercialization. Our studies and those of other groups have explored the possibility to exploit the yeast Saccharomyces cerevisiae to produce rAAV. We previously demonstrated that yeast supports AAV genome replication and capsid assembly. The purpose of this study was to evaluate the quality of the encapsidated AAV DNA. Here, we report the construction of a yeast strain expressing Rep68/40 from an integrated copy of the Rep gene under the control of the yeast constitutive ADH promoter and Capsid proteins from the Cap gene under the control of an inducible GAL promoter. Our results indicate that a portion of AAV particles generated by this system contains encapsidated AAV DNA. However, the majority of encapsidated DNA consists of fragmented regions of the transgene cassette, with ITRs being the most represented sequences. Altogether, these data indicate that, in yeast, encapsidation occurs with low efficiency and that rAAVs resemble pseudo-vectors that are present in clinical-grade rAAV preparations.
Similar content being viewed by others
References
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., et al. (2017). Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. New England Journal of Medicine, 377, 1713–1722.
Le Meur, G., Lebranchu, P., Billaud, F., Adjali, O., Schmitt, S., Bezieau, S., et al. (2018). Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis. Molecular Therapy, 26, 256–268.
Kassner, U., Hollstein, T., Grenkowitz, T., Wuhle-Demuth, M., Salewsky, B., Demuth, I., et al. (2018). Gene therapy in lipoprotein lipase deficiency: case report on the first patient treated with alipogene tiparvovec under daily practice conditions. Human Gene Therapy, 29, 520–527.
Li, C., & Samulski, R. J. (2020). Engineering adeno-associated virus vectors for gene therapy. Nature Reviews Genetics, 21, 255–272.
Hermonat, P. L., & Muzyczka, N. (1984). Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A, 81, 6466–6470.
Galibert, L., & Merten, O. W. (2011). Latest developments in the large-scale production of adeno-associated virus vectors in insect cells toward the treatment of neuromuscular diseases. Journal of Invertebrate Pathology, 107(Suppl), S80-93.
Penaud-Budloo, M., Francois, A., Clement, N., & Ayuso, E. (2018). Pharmacology of recombinant Adeno-associated virus production. Mol Ther Methods Clin Dev, 8, 166–180.
Mietzsch, M., Grasse, S., Zurawski, C., Weger, S., Bennett, A., Agbandje-McKenna, M., et al. (2014). OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1–12 vectors for gene therapy. Human Gene Therapy, 25, 212–222.
Kim, H. J. (2017). Yeast as an expression system for producing virus-like particles: what factors do we need to consider? Letters in Applied Microbiology, 64, 111–123.
Zhao, R. Y. (2017). Yeast for virus research. Microb. Cell, 4, 311–330.
Barajas, D., Aponte-Ubillus, J. J., Akeefe, H., Cinek, T., Peltier, J., & Gold, D. (2017). Generation of infectious recombinant Adeno-associated virus in Saccharomyces cerevisiae. PLoS ONE, 12, e0173010.
Cervelli, T., Backovic, A., & Galli, A. (2011). Formation of AAV single stranded DNA genome from a circular plasmid in Saccharomyces cerevisiae. PLoS ONE, 6, e23474.
Backovic, A., Cervelli, T., Salvetti, A., Zentilin, L., Giacca, M., & Galli, A. (2012). Capsid protein expression and adeno-associated virus like particles assembly in Saccharomyces cerevisiae. Microbial Cell Factories, 11, 124.
Galli, A., Della Latta, V., Bologna, C., Pucciarelli, D., Cipriani, F., Backovic, A., et al. (2017). Strategies to optimize capsid protein expression and single-stranded DNA formation of adeno-associated virus in Saccharomyces cerevisiae. Journal of Applied Microbiology, 123, 414–428.
Aponte-Ubillus, J. J., Barajas, D., Sterling, H., Aghajanirefah, A., Bardliving, C., Peltier, J., et al. (2020). Proteome profiling and vector yield optimization in a recombinant adeno-associated virus-producing yeast model. Microbiologyopen. https://doi.org/10.1002/mbo3.1136.
Ling, C., Wang, Y., Lu, Y., Wang, L., Jayandharan, G. R., Aslanidi, G. V., et al. (2015). The Adeno-Associated Virus Genome Packaging Puzzle. J Mol Genet Med 9.
Grimm, D., Kern, A., Pawlita, M., Ferrari, F., Samulski, R., & Kleinschmidt, J. (1999). Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Therapy, 6, 1322–1330.
King, J. A., Dubielzig, R., Grimm, D., & Kleinschmidt, J. A. (2001). DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO Journal, 20, 3282–3291.
Chadeuf, G., Ciron, C., Moullier, P., & Salvetti, A. (2005). Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Molecular Therapy, 12, 744–753.
Kapranov, P., Chen, L., Dederich, D., Dong, B., He, J., Steinmann, K. E., et al. (2012). Native molecular state of adeno-associated viral vectors revealed by single-molecule sequencing. Human Gene Therapy, 23, 46–55.
Nathwani, A. C., Tuddenham, E. G., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. New England Journal of Medicine, 365, 2357–2365.
de la Maza, L. M., & Carter, B. J. (1980). Molecular structure of adeno-associated virus variant DNA. Journal of Biological Chemistry, 255, 3194–3203.
Senapathy, P., & Carter, B. J. (1984). Molecular cloning of adeno-associated virus variant genomes and generation of infectious virus by recombination in mammalian cells. Journal of Biological Chemistry, 259, 4661–4666.
Wang, Q., Dong, B., Pokiniewski, K. A., Firrman, J., Wu, Z., Chin, M. P., et al. (2017). Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors. Mol Ther Methods Clin Dev, 4, 149–158.
Gietz, R. D., & Schiestl, R. H. (2007). Large-scale high-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nature Protocols, 2, 38–41.
Oldenburg, K. R., Vo, K. T., Michaelis, S., & Paddon, C. (1997). Recombination-mediated PCR-directed plasmid construction in vivo in yeast. Nucleic Acids Research, 25, 451–452.
Deodato, B., Arsic, N., Zentilin, L., Galeano, M., Santoro, D., Torre, V., et al. (2002). Recombinant AAV vector encoding human VEGF165 enhances wound healing. Gene Therapy, 9, 777–785.
Arsic, N., Zacchigna, S., Zentilin, L., Ramirez-Correa, G., Pattarini, L., Salvi, A., et al. (2004). Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo. Molecular Therapy, 10, 844–854.
Zentilin, L., Marcello, A., & Giacca, M. (2001). Involvement of cellular double-stranded DNA break binding proteins in processing of the recombinant adeno-associated virus genome. Journal of Virology, 75, 12279–12287.
Trapani, I., Toriello, E., de Simone, S., Colella, P., Iodice, C., Polishchuk, E. V., et al. (2015). Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease. Human Molecular Genetics, 24, 6811–6825.
Aurnhammer, C., Haase, M., Muether, N., Hausl, M., Rauschhuber, C., Huber, I., et al. (2012). Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum Gene Ther Methods, 23, 18–28.
Maurer, A. C., & Weitzman, M. D. (2020). Adeno-Associated Virus Genome Interactions Important for Vector Production and Transduction. Human Gene Therapy, 31, 499–511.
Dubielzig, R., King, J. A., Weger, S., Kern, A., & Kleinschmidt, J. A. (1999). Adeno-associated virus type 2 protein interactions: formation of pre-encapsidation complexes. Journal of Virology, 73, 8989–8998.
Owens, R. A., Weitzman, M. D., Kyostio, S. R., & Carter, B. J. (1993). Identification of a DNA-binding domain in the amino terminus of adeno-associated virus Rep proteins. Journal of Virology, 67, 997–1005.
Im, D. S., & Muzyczka, N. (1990). The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity. Cell, 61, 447–457.
Prasad, K. M., & Trempe, J. P. (1995). The adeno-associated virus Rep78 protein is covalently linked to viral DNA in a preformed virion. Virology, 214, 360–370.
Myers, M. W., & Carter, B. J. (1981). Adeno-associated virus replication. The effect of L-canavanine or a helper virus mutation on accumulation of viral capsids and progeny single-stranded DNA. Journal of Biological Chemistry, 256, 567–570.
McCarty, D. M., Pereira, D. J., Zolotukhin, I., Zhou, X., Ryan, J. H., & Muzyczka, N. (1994). Identification of linear DNA sequences that specifically bind the adeno-associated virus Rep protein. Journal of Virology, 68, 4988–4997.
Nony, P., Tessier, J., Chadeuf, G., Ward, P., Giraud, A., Dugast, M., et al. (2001). Novel cis-acting replication element in the adeno-associated virus type 2 genome is involved in amplification of integrated rep-cap sequences. Journal of Virology, 75, 9991–9994.
Nony, P., Chadeuf, G., Tessier, J., Moullier, P., & Salvetti, A. (2003). Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) type 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles. Journal of Virology, 77, 776–781.
Yoon-Robarts, M., Blouin, A. G., Bleker, S., Kleinschmidt, J. A., Aggarwal, A. K., Escalante, C. R., et al. (2004). Residues within the B’ motif are critical for DNA binding by the superfamily 3 helicase Rep40 of adeno-associated virus type 2. Journal of Biological Chemistry, 279, 50472–50481.
Dong, B., Nakai, H., & Xiao, W. (2010). Characterization of genome integrity for oversized recombinant AAV vector. Molecular Therapy, 18, 87–92.
Wu, Z., Yang, H., & Colosi, P. (2010). Effect of genome size on AAV vector packaging. Molecular Therapy, 18, 80–86.
D’Costa, S., Blouin, V., Broucque, F., Penaud-Budloo, M., Francois, A., Perez, I. C., et al. (2016). Practical utilization of recombinant AAV vector reference standards: focus on vector genomes titration by free ITR qPCR. Mol Ther Methods Clin Dev, 5, 16019.
Werling, N. J., Satkunanathan, S., Thorpe, R., & Zhao, Y. (2015). Systematic Comparison and Validation of Quantitative Real-Time PCR Methods for the Quantitation of Adeno-Associated Viral Products. Hum Gene Ther Methods, 26, 82–92.
Dobnik, D., Kogovsek, P., Jakomin, T., Kosir, N., Tusek Znidaric, M., Leskovec, M., et al. (2019). Accurate Quantification and Characterization of Adeno-Associated Viral Vectors. Front Microbiol, 10, 1570.
Berns, K. I., & Rose, J. A. (1970). Evidence for a single-stranded adenovirus-associated virus genome: isolation and separation of complementary single strands. Journal of Virology, 5, 693–699.
Zhou, X., Zeng, X., Fan, Z., Li, C., McCown, T., Samulski, R. J., et al. (2008). Adeno-associated virus of a single-polarity DNA genome is capable of transduction in vivo. Molecular Therapy, 16, 494–499.
McAlister, V. J., & Owens, R. A. (2010). Substitution of adeno-associated virus Rep protein binding and nicking sites with human chromosome 19 sequences. Virol J, 7, 218.
Qu, G., Bahr-Davidson, J., Prado, J., Tai, A., Cataniag, F., McDonnell, J., et al. (2007). Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. Journal of Virological Methods, 140, 183–192.
Samulski, R. J., & Muzyczka, N. (2014). AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. Annu Rev Virol, 1, 427–451.
Aponte-Ubillus, J. J., Barajas, D., Peltier, J., Bardliving, C., Shamlou, P., & Gold, D. (2018). Molecular design for recombinant adeno-associated virus (rAAV) vector production. Applied Microbiology and Biotechnology, 102, 1045–1054.
Aponte-Ubillus, J. J., Barajas, D., Peltier, J., Bardliving, C., Shamlou, P., & Gold, D. (2019). A rAAV2-producing yeast screening model to identify host proteins enhancing rAAV DNA replication and vector yield. Biotechnology Progress, 35, e2725.
Acknowledgements
This work was supported by the Grant 127/16 funded by the “Fondazione Pisa” assigned to AG. We thank Dr Milena Rizzo for helpful suggestions on qPCR. We thanks also Marina Dapas and Michela Zotti of the AVU (AAV vector unit) core facility of ICGEB, Trieste, for AAV production in human cells.
Author information
Authors and Affiliations
Contributions
AG and TC designed the study. LZ produced rAAV from human cells. II, SM, FC and VD performed the study. AG, II, SM, FC, VD and TC analysed the results. LZ, MG, AG and TC discussed the results. AG and TC wrote the manuscript. All authors revised the manuscript and agreed to be accountable for all aspects of the presented work.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest with the contents of this article.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Galli, A., Iaia, I., Milella, M.S. et al. Characterization of Viral Genome Encapsidated in Adeno-associated Recombinant Vectors Produced in Yeast Saccharomyces cerevisiae. Mol Biotechnol 63, 156–165 (2021). https://doi.org/10.1007/s12033-020-00294-4
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12033-020-00294-4